Progress and controversies in neoadjuvant therapy

被引：0
|
作者：
Edwin M. Posadas
Robert A. Figlin
机构：
[1] Urologic Oncology Program,
[2] Samuel Oschin Comprehensive Cancer Institute,undefined
[3] Cedars–Sinai Medical Center,undefined
来源：
Nature Reviews Urology | 2014年 / 11卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Use of clinically active agents, such as kinase inhibitors, before nephrectomy is safe and feasible and can decrease the size of primary tumours, enabling optimization of the surgical approach. However, the overall clinical benefit of the neoadjuvant use of toxic drugs, such as axitinib, has not yet been demonstrated.
引用
收藏
页码：254 / 256
页数：2
相关论文
共 50 条
  • [21] PROGRESS AND CONTROVERSIES IN NEUROPSYCHOLOGY OF MEMORY
    GAINOTTI, G
    MARRA, C
    ACTA NEUROLOGICA, 1992, 14 (4-6) : 561 - 577
  • [22] Research progress on immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer
    Wenting Li
    Shiying Yu
    Oncology and Translational Medicine, 2022, 8 (02) : 74 - 82
  • [23] Neoadjuvant Therapy for Early-Stage Breast Cancer: Current Practice, Controversies, and Future Directions
    Santa-Maria, Cesar Augusto
    Camp, Melissa
    Cimino-Mathews, Ashley
    Harvey, Susan
    Wright, Jean
    Stearns, Vered
    ONCOLOGY-NEW YORK, 2015, 29 (11): : 828 - 838
  • [24] Neoadjuvant treatment for pancreatic cancer: Controversies and advances
    Silva, Douglas Dias
    Chung, Vincent
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 39
  • [25] Current Controversies in Neoadjuvant Chemoradiation of Rectal Cancer
    Phang, P. Terry
    Wang, Xiaodong
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 23 (01) : 79 - +
  • [26] Optimizing HER2-positive breast cancer therapy through neoadjuvant platforms: controversies and concepts
    Wu, Shuang-Ling
    Xu, Ying-Ying
    TRANSLATIONAL BREAST CANCER RESEARCH, 2021, 2
  • [27] Neoadjuvant Therapy for Breast Cancer: Assessing Treatment Progress and Managing Poor Responders
    Wesolowski, Robert
    Budd, George Thomas
    CURRENT ONCOLOGY REPORTS, 2009, 11 (01) : 37 - 44
  • [28] Neoadjuvant therapy for breast cancer: Assessing treatment progress and managing poor responders
    Wesolowski R.
    Budd G.T.
    Current Breast Cancer Reports, 2009, 1 (1) : 21 - 28
  • [29] Neoadjuvant therapy for breast cancer: Assessing treatment progress and managing poor responders
    Robert Wesolowski
    George Thomas Budd
    Current Oncology Reports, 2009, 11 : 37 - 44
  • [30] ACUTE MYELOGENOUS LEUKEMIA - PROGRESS AND CONTROVERSIES
    GALE, RP
    LEUKEMIA, 1990, 4 (07) : 529 - 531
12345